Price (90d)
$43.83Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.45B | $49.22M | $0.79 |
| 2024 | $1.23B | $-87.29M | $-1.77 |
| 2023 | $1.05B | $23.90M | $0.39 |
| 2022 | $908.91M | $35.42M | $0.58 |
| 2021 | $792.07M | $16.31M | $0.27 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $0.31 per share
Typical surprise +10.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.29 vs $0.26beat
- Wed, May 6$0.29 vs $0.24beat
- Wed, Mar 11$0.37 vs $0.27beat
- Mon, Nov 10$0.25 vs $0.24beat
- Mon, Aug 11$0.23 vs $0.22beat
- Mon, May 12$0.21 vs $0.22miss
Estimates and results for GRDN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GRDN's reported EPS growth of 30.8% a year over 4 years. Historical EPS growth of 31% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $2.93
- Implied price
- $111.31
- Return from $38.43
- 23.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $55.34 — today's price is already 30.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 32 | 38 | 44 | 50 |
|---|---|---|---|---|---|
| 20.0% | 5.8% | 10.3% | 14.2% | 17.6% | 20.6% |
| 25.0% | 10.3% | 14.9% | 18.9% | 22.5% | 25.7% |
| 30.0% | 14.7% | 19.5% | 23.7% | 27.4% | 30.7% |
| 35.0% | 19.1% | 24.1% | 28.5% | 32.3% | 35.7% |
| 40.0% | 23.5% | 28.7% | 33.2% | 37.2% | 40.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsmarketbeat.com·7d ago·Negative
Guardian Pharmacy Services Q2 Earnings Call Highlights Guardian Pharmacy Services NYSE: GRDN reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.
View source ↗